BACKGROUND AND OBJECTIVES: Polymorphisms of the VEGF gene are known to affect the biological behaviour of cancers but have seldom been studied in thyroid cancer. The aim of the current study is to evaluate the prevalence and relevance of VEGF-A polymorphisms and mRNA expression in papillary thyroid carcinoma (PTC). MATERIALS AND METHODS: Genomic DNA and total RNA were isolated from paraffin-embedded tissue from 91 PTC (51 conventional PTC and 40 follicular variant) and 78 control thyroid tissues. Three DNA polymorphisms (+936C > T, +405C > G and -141A > C) in the 3' and 5' untranslated region (3'-UTR, 5'-UTR) of VEGF-A were studied using PCR and RFLP. Also, the mRNA expression of VEGF-A in these tissues was studied by real-time PCR. RESULTS: Distribution of polymorphisms in the 5'-UTR (VEGF-VEGF -141A > C and +405C > G) and 3'-UTR (VEGF +936C > T) were all significantly different in PTC and benign thyroid tissue (p = 0.0001, 0.001 and 0.028 respectively). The VEGF -141 C allele was more common in PTC with lymph node metastases (p = 0.026). VEGF + 405 Galleles andVEGF +936 CC genotype were more common in PTC of advanced pathological staging (p = 0.018 and 0.017 respectively). Also, increased expression of VEGF-A mRNA was noted in PTC compared to control (p = 0.009). Within the group of patients with conventional PTC, those with lymph nodal metastases had a higher level of VEGF-A mRNA expression than other patients (p = 0.0003). CONCLUSION: These findings suggest that VEGF polymorphisms and mRNA expression may predict the aggressiveness behaviour of thyroid cancer.
BACKGROUND AND OBJECTIVES: Polymorphisms of the VEGF gene are known to affect the biological behaviour of cancers but have seldom been studied in thyroid cancer. The aim of the current study is to evaluate the prevalence and relevance of VEGF-A polymorphisms and mRNA expression in papillary thyroid carcinoma (PTC). MATERIALS AND METHODS: Genomic DNA and total RNA were isolated from paraffin-embedded tissue from 91 PTC (51 conventional PTC and 40 follicular variant) and 78 control thyroid tissues. Three DNA polymorphisms (+936C > T, +405C > G and -141A > C) in the 3' and 5' untranslated region (3'-UTR, 5'-UTR) of VEGF-A were studied using PCR and RFLP. Also, the mRNA expression of VEGF-A in these tissues was studied by real-time PCR. RESULTS: Distribution of polymorphisms in the 5'-UTR (VEGF-VEGF -141A > C and +405C > G) and 3'-UTR (VEGF +936C > T) were all significantly different in PTC and benign thyroid tissue (p = 0.0001, 0.001 and 0.028 respectively). The VEGF -141 C allele was more common in PTC with lymph node metastases (p = 0.026). VEGF + 405 Galleles andVEGF +936 CC genotype were more common in PTC of advanced pathological staging (p = 0.018 and 0.017 respectively). Also, increased expression of VEGF-A mRNA was noted in PTC compared to control (p = 0.009). Within the group of patients with conventional PTC, those with lymph nodal metastases had a higher level of VEGF-A mRNA expression than other patients (p = 0.0003). CONCLUSION: These findings suggest that VEGF polymorphisms and mRNA expression may predict the aggressiveness behaviour of thyroid cancer.
Authors: A Molinaro; P Orlandi; F Niccolai; P Agretti; G De Marco; E Ferrarini; C Di Cosmo; P Vitti; P Piaggi; T Di Desidero; G Bocci; M Tonacchera Journal: J Endocrinol Invest Date: 2019-08-02 Impact factor: 4.256
Authors: Mi Kyeong Kim; Sung Wook Park; Su Kang Kim; Hae Jeong Park; Young Gyu Eun; Kee Hwan Kwon; Jinju Kim Journal: J Korean Med Sci Date: 2012-10-30 Impact factor: 2.153
Authors: Young Gyu Eun; Il Ki Hong; Su Kang Kim; Hyun-Kyung Park; Sam Kwon; Dae Han Chung; Kee Hwan Kwon Journal: Clin Exp Otorhinolaryngol Date: 2011-09-06 Impact factor: 3.372
Authors: Eleonora Porcu; Marco Medici; Giorgio Pistis; Claudia B Volpato; Scott G Wilson; Anne R Cappola; Steffan D Bos; Joris Deelen; Martin den Heijer; Rachel M Freathy; Jari Lahti; Chunyu Liu; Lorna M Lopez; Ilja M Nolte; Jeffrey R O'Connell; Toshiko Tanaka; Stella Trompet; Alice Arnold; Stefania Bandinelli; Marian Beekman; Stefan Böhringer; Suzanne J Brown; Brendan M Buckley; Clara Camaschella; Anton J M de Craen; Gail Davies; Marieke C H de Visser; Ian Ford; Tom Forsen; Timothy M Frayling; Laura Fugazzola; Martin Gögele; Andrew T Hattersley; Ad R Hermus; Albert Hofman; Jeanine J Houwing-Duistermaat; Richard A Jensen; Eero Kajantie; Margreet Kloppenburg; Ee M Lim; Corrado Masciullo; Stefano Mariotti; Cosetta Minelli; Braxton D Mitchell; Ramaiah Nagaraja; Romana T Netea-Maier; Aarno Palotie; Luca Persani; Maria G Piras; Bruce M Psaty; Katri Räikkönen; J Brent Richards; Fernando Rivadeneira; Cinzia Sala; Mona M Sabra; Naveed Sattar; Beverley M Shields; Nicole Soranzo; John M Starr; David J Stott; Fred C G J Sweep; Gianluca Usala; Melanie M van der Klauw; Diana van Heemst; Alies van Mullem; Sita H Vermeulen; W Edward Visser; John P Walsh; Rudi G J Westendorp; Elisabeth Widen; Guangju Zhai; Francesco Cucca; Ian J Deary; Johan G Eriksson; Luigi Ferrucci; Caroline S Fox; J Wouter Jukema; Lambertus A Kiemeney; Peter P Pramstaller; David Schlessinger; Alan R Shuldiner; Eline P Slagboom; André G Uitterlinden; Bijay Vaidya; Theo J Visser; Bruce H R Wolffenbuttel; Ingrid Meulenbelt; Jerome I Rotter; Tim D Spector; Andrew A Hicks; Daniela Toniolo; Serena Sanna; Robin P Peeters; Silvia Naitza Journal: PLoS Genet Date: 2013-02-07 Impact factor: 5.917